PALISADE BIO INC (PALI)
Health Care · Clinical-stage biopharmaceutical development · NASDAQ
A clinical-stage biotech developing PALI-2108, a licensed small-molecule candidate in Phase 1 trials, with a capital-dependent model dependent on licensing agreements and third-party manufacturing.
What PALISADE BIO INC does
Palisade Bio is a clinical-stage biopharmaceutical company focused on the development of PALI-2108, its lead asset licensed from Giiant Pharma Inc. The company is currently conducting a Phase 1 clinical trial of PALI-2108 and relies on third-party contract research organizations and suppliers for clinical trial execution and manufacturing. Palisade has limited operating history, has never generated product revenues, and is pursuing a business model based on the development and potential commercialization or out-licensing of its product candidates.
Themes: ["clinical-stage biopharmaceutical development","Phase 1 drug candidates","drug licensing and out-licensing"]
Fundamentals
- Price$1.97 as of 2026-07-09 close
- Market cap$340M as of 2026-07-10
- 1-year return+159.2% as of 2026-07-09 close
- Net margin-936.0% as of 2026-07-10
- ROE-36.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.45 as of 2026-07-10
Key risks (from latest filing)
["PALI-2108 is in early-stage clinical development with substantial drug development risk; failure to generate successful Phase 1 data or inability to enroll patients could prevent advancement to later-stage trials and regulatory approval","Dependence on the Giiant Pharma license agreement for PALI-2108 patent rights; termination of the license or failure to comply with obligations could prevent development or commercialization of the lead asset","Limited capital and uncertain ability to secure additional funding required for continued operations and clinical development of PALI-2108"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.